[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589161":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":10,"centralContacts":21,"locations":27,"responsibleParty":44,"collaborators":10,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":10,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":10,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":10,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"West China Hospital","OTHER",[8,13],{"label":9,"type":10,"description":10,"interventionNames":11},"Primary hepatic sarcomatoid carcinoma patients who received adjuvant therapy",null,[12],"Procedure: postoperative adjuvant therapy",{"label":14,"type":10,"description":10,"interventionNames":10},"Primary hepatic sarcomatoid carcinoma patients who did not receive adjuvant therapy",[16],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":10},"PROCEDURE","postoperative adjuvant therapy","Given the rarity and high aggressiveness of PHSC, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines.",[9],[22],{"name":23,"role":24,"phone":25,"phoneExt":10,"email":26},"Jiwei Huang Professor","CONTACT","+86 18980606725","huangjiwei@wchscu.cn",[28],{"facility":5,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"RECRUITING","Chengdu","Sichuan","610041","China","CN",{"type":36,"coordinates":37},"Point",[38,39],104.06667,30.66667,{"lat":39,"lon":38},[42],{"name":43,"role":24,"phone":25,"phoneExt":10,"email":26},"Jiwei Huang Huang Professor",{"type":45,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Jiwei Huang","Clinical Professor","100589161","prognostic-impact-of-adjuvant-therapy-in-primary-hepatic-sarcomatoid-carcinoma-100589161",false,"NCT06950814","Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma","Prognostic Impact of Adjuvant Therapy Following Surgical Resection in Primary Hepatic Sarcomatoid Carcinoma: A Retrospective Cohort Study","Inclusion Criteria:\n\n1. patients who underwent liver resection\n2. patients' postoperative paraffin pathology and immunohistochemistry results were reviewed to identify those diagnosed with PHSC\n\nExclusion Criteria:\n\n1. patients who received other anti-tumor treatments before surgery, such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), radiation therapy (RT), and systemic therapy;\n2. patients diagnosed with other specific types of sarcomas;\n3. patients with concurrent other malignancies during the course of PHSC;\n4. patients who were lost to follow-up or lacked essential clinical data.","ALL","18 Years",{"count":58,"type":59},50,"ESTIMATED","OBSERVATIONAL","In recent years, researchers have conducted extensive studies on adjuvant therapy following surgical resection of liver cancer, exploring its potential benefits and seeking effective treatment strategies. Given the rarity and high aggressiveness of primary hepatic sarcomatoid carcinoma, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines. Therefore, we conducted a single-center retrospective study to assess the potential benefits of postoperative adjuvant therapy for patients of primary hepatic sarcomatoid carcinoma.",[63,64,65],"Sarcomatoid Carcinoma","Liver Cancer","Adjuvant Therapy","2025-04-22",{"date":68,"type":69},"2025-04-30","ACTUAL",{"date":71,"type":69},"2025-04-05",{"date":73,"type":59},"2025-05-05",{"name":5,"class":6},1]